It has agreed to acquire a trispecific T cell-engager for multiple myeloma from privately held Chimagen Biosciences, in a deal worth up to $750 million.

A phase III trial in China showed GSK's licensed antibody-drug conjugate Ris-Rez extended survival in relapsed small cell lung cancer patients versus standard chemotherapy.

Japan's health ministry approved a ready-to-use presentation of GSK's shingles vaccine, following its US launch earlier this year.

GSK will start Phase III trials in September for its mRNA flu vaccine after early data showed stronger immune responses than existing licensed shots.

The US regulator will decide by February 2027 whether to approve the drug for a subset of previously untreated locally advanced rectal cancer patients.

Japan's health ministry approved GSK's bepirovirsen as a functional cure for chronic hepatitis B, marking the treatment's first regulatory clearance anywhere in the world.

DB analyst Emmanuel Papadakis repeated a Hold rating and 1,950p price target, after the drugmaker's camlipixant programme delivered mixed late-stage trial results, widening the gap to its 2031 sales ambition.

The European Medicines Agency will review a label update allowing a single Bexsero booster dose for people aged 10 and over previously vaccinated against meningitis B.

GSK will halt further development of camlipixant for refractory chronic cough after one of two pivotal trials failed to hit its primary goal.

GSK has closed its takeover of Boston-based Nuvalent, bringing three targeted lung cancer therapies into its oncology pipeline.

Positive interim results for its immunotherapy Jemperli in a phase II trial for dMMR/MSI-H locally advanced rectal cancer, raise the prospect that some patients could avoid chemotherapy, radiation and surgery.

Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.

Analyst Emmanuel Papadakis sees double-digit upside for Shingrix and Apretude but double-digit downside for Trelegy and Triumeq as weekly Rx data through 12 June holds prior-week patterns.

VEXAS syndrome affects tens of thousands of patients worldwide and carries a five-year mortality rate of 30% to 40%.

"The two lead products are potential best‑in‑class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non‑small cell lung cancer," said Luke Miels, Chief Executive Officer.

“For the first time, bepirovirsen offers the possibility of significantly better functional cure rates than the current standard of care," said Tony Wood, GSK’s Chief Scientific Officer.

"This expanded approval, the first covering all at-risk adults in Japan, can help reduce potentially severe outcomes of RSV," said Sanjay Gurunathan.

An exclusive strategic collaboration with Sino Biopharmaceutical's Chia Tai Tianqing (CTTQ) aims to manage importation, distribution and hospital access for bepirovirsen in mainland China.

A once-monthly investigational therapy efimosfermin has been granted Breakthrough Therapy designation by the US FDA and PRIME status by the EMA after Phase II data showed improved liver fibrosis and MASH resolution in patients with F2/F3 disease.

GSK has secured NMPA approval in China for Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone for adults after at least one prior therapy, after DREAMM‑7 showed a 42% reduction in risk of death and nearly tripled median PFS versus a daratumumab-based triplet.

GSK says an estimated 21.3 million US adults aged 20–49 have at least one risk factor for severe RSV disease